healthcare-biosimilars-2018-keynote

Page 34

Notes:

allied

academies

Asian Journal of Biomedical and Pharmaceutical Sciences | Volume 8

March 26-27, 2018 | Orlando, USA

World Summit on

Healthcare & Hospital Management

International Conference & Exhibition on

Biologics and Biosimilars

Kiminobu Sugaya

University of Central Florida, USA

Small molecule drug therapy to increase neurogenesis in Alzheimer’s disease

espite decades of investigations in both basic and clinic, the

cause of Alzheimer’s disease (AD) still remains unknown.

Current problem of developing AD research is that many

treatments are focusing AD hallmarks, amyloid plaque and

neurofibrillary tangles, and they have been very effective in AD

animal models but never be successful showing any significant

effect in clinical trials. Thus, establishment of an effective

treatment in a model, which represents pathophysiology of

AD is needed. Previously, we were able to show improved

cognitive function of aged, memory-impaired animals through

the implantation of human neural stem cells (NSCs), which

produced much excitement throughout the research world and

the overall medical community; given the implication that this

could lead toa cure for all neurodegenerativediseases, including

AD. However, when we transplant NSCs to a transgenic animal

model produces Amyloid-β (Aβ) plaque formation in the brain

by expressing familial AD mutant amyloid precursor protein

(APP), mimicking the pathological condition of AD, we did not

find any new neuronal development formed from the donor

cells. This indicates that transplantation of NSCs by itself may

not be a cure for AD. Here, we show that the combination drug

therapy of Phenserine (reduce APP level) and NBI-18 (increase

endogenous NSCs) increased neurogenesis and significantly

improved memory in the transgenic AD mouse model. This

combination therapy could bring us an effective treatment

for AD. I will further discuss the use of iPS cell to confirm the

efficacy of this therapy

in vitro

3D human AD brain model.

Speaker Biography

Kiminobu Sugaya is a Professor of Medicine, the Head of Neuroscience and the Chair

of Multidisciplinary Neuroscience Alliance, Burnett School of Biomedical Sciences-

College of Medicine University of Central Florida.